Currently, there are 3.10B common shares owned by the public and among those 3.10B shares have been available to trade.
However, the script later moved the day high at 65.64, down -0.76%. The company’s stock has a 5-day price change of -3.05% and 1.50% over the past three months. AZN shares are trading -3.28% year to date (YTD), with the 12-month market performance up to 3.15% higher. It has a 12-month low price of $61.73 and touched a high of $76.56 over the same period. AZN has an average intraday trading volume of 5.43 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -3.45%, -1.61%, and -5.00% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Astrazeneca plc ADR (NASDAQ: AZN) shares accounts for 16.00% of the company’s 3.10B shares outstanding.
It has a market capitalization of $201.96B and a beta (3y monthly) value of 0.52. The stock’s trailing 12-month PE ratio is 34.45, while the earnings-per-share (ttm) stands at $1.89. The company has a PEG of 2.63 and a Quick Ratio of 0.60 with the debt-to-equity ratio at 0.77. Price movements for the stock have been influenced by the stock’s volatility, which stands at 1.14% over the week and 1.14% over the month.
Analysts forecast that Astrazeneca plc ADR (AZN) will achieve an EPS of $0.79 for the current quarter, $1.01 for the next quarter and $4.22 for 2024. The lowest estimate earnings-per-share for the quarter is $0.72 while analysts give the company a high EPS estimate of $0.87. Comparatively, EPS for the current quarter was $0.69 a year ago. Earnings per share for the fiscal year are expected to increase by 9.41%, and 13.15% over the next financial year. EPS should grow at an annualized rate of 13.10% over the next five years, compared to -2.17% over the past 5-year period.
Looking at the support for the AZN, a number of firms have released research notes about the stock. Morgan Stanley stated their Overweight rating for the stock in a research note on January 23, 2024, with the firm’s price target at $85.
